Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EIF4E | P06730 | 19/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23457475 | 1.00 | KDM4E (0.50) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL27971304 | 0.78 | AHR (0.48) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL30918738 | 0.78 | AHR (0.48) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL28321643 | 0.75 | KDM4E (0.50) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL28876683 | 0.74 | KDM4E (0.49) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL28321645 | 0.74 | ALDH1A1 (0.53) | KDM4EMEN1RAB9AKMT2AEIF4E | |
| SCHEMBL26124619 | 0.74 | EIF4E (0.64) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL28320520 | 0.73 | PIM1 (0.45) | KDM4ERAB9AEIF4E | |
| SCHEMBL16399594 | 0.72 | EIF4E (0.48) | KDM4EMEN1NPC1RAB9AKMT2A | |
| SCHEMBL17969182 | 0.72 | EIF4E (0.48) | KDM4EMEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KDM4E 3645/4885MEN1 2988/4885NPC1 1158/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KDM4E 3325/4885MEN1 2927/4885NPC1 1113/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | KDM4E 3645/4885MEN1 2988/4885NPC1 1158/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KDM4E 3645/4885MEN1 2988/4885NPC1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.